Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 25;9(1):15373.
doi: 10.1038/s41598-019-51867-6.

Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study

Affiliations

Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study

Francesca Romana Ponziani et al. Sci Rep. .

Abstract

Minimal hepatic encephalopathy (MHE) is a subclinical complication of liver cirrhosis with a relevant social impact. Thus, there is urgent need to implement easy to use diagnostic tools for the early identification of affected patients. The aim of this study was to investigate cerebral blood flow, systemic hemodynamics as well as endothelial function of cirrhotic patients with MHE, and to verify their change after treatment with rifaximin. Fifty cirrhotic patients with or without MHE and an equal number of healthy controls underwent transcranial Doppler ultrasound (TCD), abdominal Doppler ultrasound (US), and measurement of flow mediated dilation (FMD). In cirrhotic patients diagnosed with MHE receiving rifaximin, the tests were repeated at the end of treatment. Middle (MCA) and posterior (PCA) cerebral artery resistive (RI) and pulsatility (PI) indices were higher in cirrhotic patients than controls, as well as renal and splenic artery RI. Conversely, FMD was reduced. MCA-RI and PI were even higher in cirrhotic patients with MHE compared to those without; a MCA-RI cut-off of 0.65 showed an accuracy of 74% in discriminating the presence of MHE, with 65% sensitivity and 76% specificity. Rifaximin treatment showed no efficacy in the modulation of cerebral vascular flow. In conclusion, cirrhotic patients with MHE have significantly increased cerebral vascular resistances that are not improved by rifaximin treatment. MCA-RI measurement has a good accuracy for the diagnosis of MHE and can be useful for the early identification of this harmful complication of liver cirrhosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Correlations between systemic and splanchnic vascular resistance parameters and flow mediated dilation (FMD) in the study population. Positive correlations are represented in dark green, negative ones in light green. The size of the circle and color intensity are proportional to the correlation coefficient. RI = resistive index; PI = pulsatility index; MCA = middle cerebral artery; PCA = posterior cerebral artery; RA = renal artery; SA = splenic artery; MPV = mean portal vein velocity; FMD = flow mediated dilation.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curve of middle cerebral artery resistive index (MCA-RI) for discriminating the presence or the absence of minimal hepatic encephalopathy (MHE). The cut-off value of 0.65 resulted in the best accuracy (74%), with 65% sensitivity and 76% specificity.
Figure 3
Figure 3
Change in cerebral and splanchnic vascular resistance parameters, flow mediated dilation (FMD), neuropsychological tests results (expressed as rough or standardized values) and ammonia serum level after rifaximin treatment in cirrhotic patients with minimal hepatic encephalopathy (MHE). RI = resistive index; PI = pulsatility index; MCA = middle cerebral artery; PCA = posterior cerebral artery; RA = renal artery; SA = splenic artery; MPV = mean portal vein velocity; FMD = flow mediated dilation; TMT = trail making test; DST = digit symbol test.

References

    1. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(Suppl 1):3–9. doi: 10.1111/j.1746-6342.2006.03215.x. - DOI - PubMed
    1. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis. 2001;16:37–41. doi: 10.1023/A:1011610427843. - DOI - PubMed
    1. Groeneweg M, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28:45–49. doi: 10.1002/hep.510280108. - DOI - PubMed
    1. Amodio P, et al. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999;29:1662–1667. doi: 10.1002/hep.510290619. - DOI - PubMed
    1. Dhiman RK, et al. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. 2010;55:2381–2390. doi: 10.1007/s10620-010-1249-7. - DOI - PubMed

MeSH terms